Leadership & Expert Views - Cancer Currents Blog
Commentaries from scientific leaders at NCI and other institutions about cancer research topics, programs, and initiatives.
-
FDA’s approval of pembrolizumab (Keytruda) to treat people whose cancer is tumor mutational burden-high highlights the importance of genomic testing to guide treatment, including for children with cancer, according to NCI Director Dr. Ned Sharpless.
-
NCI has launched the COVID-19 in Cancer Patients Study (NCCAPS), which will help answer questions about COVID-19’s impact on cancer patients. The study is now open to adults and will later be expanded to include children.
-
On January 1, 2020, the Food and Drug Administration (FDA) began requiring food manufacturers to display updated nutrition facts labels on their product packaging. Experts from FDA and NCI discuss the update and the research that underpins the changes.
-
NCI is lending its tremendous expertise and unique research capabilities to the global response to the COVID-19 pandemic. NCI Director Dr. Norman Sharpless describes some of the COVID-19 specific research activities NCI has initiated.
-
NCI’s Center for Cancer Training (CCT) develops training and career development programs for the next generation of cancer researchers. Here, the new CCT director discusses his goals for CCT and the challenges of training cancer researchers.
-
Hundreds of investigators participating in the Cancer Moonshot℠ to accelerate cancer research met recently to provide updates on their progress since the initiative was announced in 2016.
-
Dr. Teresa Woodruff discusses the field that connects oncology with reproductive health, and the Oncofertility Consortium’s efforts to support clinicians, cancer patients, and families in understanding how cancer and its treatment affect fertility.
-
Updated guidelines on exercise for those living with cancer and cancer survivors were recently released. In this conversation, Dr. Kathryn Schmitz discusses what these new guidelines mean for doctors, patients, and survivors.
-
Dr. Ned Sharpless discusses his return as NCI director after serving as acting commissioner of the Food and Drug Administration for 7 months.
-
NCI Acting Director Douglas Lowy, M.D., discusses the institute’s Annual Plan & Budget Proposal for Fiscal Year 2021, which includes the institute’s professional judgement on the funding required to make the most rapid progress against cancer.